Information for "Chemistry:NNI-351"
From HandWiki
Basic information
| Display title | Chemistry:NNI-351 |
| Default sort key | NNI-351 |
| Page length (in bytes) | 4,056 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 769556 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | imported>NBrush |
| Date of page creation | 03:16, 6 February 2024 |
| Latest editor | imported>NBrush |
| Date of latest edit | 03:16, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Page properties
SEO properties
Description | Content |
Article description: (description)This attribute controls the content of the description and og:description elements. | NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human... |
